Linda Elliston

2022

• McAllister, B. et al. 2022. Exome sequencing of individuals with Huntington’s disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset. Nature Neuroscience 25, pp. 446-457. (10.1038/s41593-022-01033-5)

2015

• Bayram-Weston, Z. et al. 2015. Similar striatal gene expression profiles in the striatum of the YAC128 and HdhQ150 mouse models of Huntington's disease are not reflected in mutant Huntingtin inclusion prevalence. BMC Genomics 16, pp. -., article number: 1079. (10.1186/s12864-015-2251-4)

2014

• Hughes, A., Mort, M. E., Elliston, L. A., Thomas, R. M., Brooks, S. P., Dunnett, S. B. and Jones, L. 2014. Identification of novel alternative splicing events in the Huntingtin gene and assessment of the functional consequences using structural protein homology modelling. Journal of Molecular Biology 426(7), pp. 1428-1438. (10.1016/j.jmb.2013.12.028)

2013

• Taylor, D. M. et al. 2013. MAP Kinase Phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's Disease via additive effects of JNK and p38 inhibition. Journal of Neuroscience 33(6), pp. 2313-2325. (10.1523/JNEUROSCI.4965-11.2013)

2012

• Giles, P. J., Elliston, L. A., Higgs, G., Brooks, S. P., Dunnett, S. B. and Jones, L. 2012. Longitudinal analysis of gene expression and behaviour in the HdhQ150 mouse model of Huntington's disease. Brain Research Bulletin 88(2-3), pp. 199-209. (10.1016/j.brainresbull.2011.10.001)

2010

• Hughes, A., Ersoy, N., Elliston, L. A. and Jones, L. 2010. Protein localisation studies: Where is Huntingtin hiding? [Meeting abstract]. Journal of Neurology, Neurosurgery and Psychiatry 81(1), pp. A1. (10.1136/jnnp.2010.222570.3)

2008

• Hodges, A. K., Hughes, G., Brooks, S. P., Elliston, L. A., Holmans, P. A., Dunnett, S. B. and Jones, L. 2008. Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease. Genes, Brain and Behavior 7(3), pp. 288-299. (10.1111/j.1601-183X.2007.00350.x)
• Bray, N. J. et al. 2008. Cis- and trans- loci influence expression of the schizophrenia susceptibility gene DTNBP1. Human Molecular Genetics 17(8), pp. 1169-1174. (10.1093/hmg/ddn006)

2006

• Hodges, A. K. et al. 2006. Regional and cellular gene expression changes in human Huntington's disease brain. Human Molecular Genetics 15(6), pp. 965-977. (10.1093/hmg/ddl013)

2005

• Hodges, A. et al. 2005. Regional specificity of transcriptional changes in early grade Huntington's disease brain. Journal of Neurology, Neurosurgery and Psychiatry 76, pp. A16-A16.
• Jones, L., Elliston, L. A., Caswell, R. and Ersoy, N. 2005. Mutant huntingtin represses transcription from the thyroid hormone receptor. Journal of Neurology, Neurosurgery and Psychiatry 76, pp. A17-A17.

2002

• Duce, J., Hartog, C., Elliston, L. A., Neal, J. W., Nicholson, L. F. B. and Jones, L. 2002. Transcriptional dysregulation in Huntington's disease. American Journal of Human Genetics 69(4), pp. 545-545. (10.1007/978-1-4615-0715-4_49)

2001

• Harper, P., Evans, R., Elliston, L., Ironside, J. W., Jones, L. and Lazarou, L. 2001. Huntington's disease intermediate allele and new variant CJD. American Journal of Human Genetics 69(4), pp. 547-547.
• Jones, L., Duce, J., Elliston, L. and Harper, P. 2001. The involvement of transcriptional repressor proteins in Huntington's disease. Journal of Medical Genetics 38(Suppl1), pp. S65-S65.